Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6007 in moderate active ulcerative colitis
NCT03018054Phase 2Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of milategrast in ulcerative colitis (UC) (3 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Change from Baseline in Mayo score at 8 weeks. Started Nov 2016; status: completed.
02
Drugs
milategrast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03018054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018054.